IgA nephropathy
Conditions
Interventions
Budesonide enteric-coated capsules immunosuppressant (cyclophosphamide/mycophenolate mofetil) combination therapy group:None
Budesonide enteric-coated capsule treatment group:None
Sponsors
The First Affiliated Hospital of Air Force Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: ??(1) Obtain written informed consent;?? ??(2) Aged 18-80 years;?? ??(3) Confirmed diagnosis of IgAN by renal pathological biopsy;?? ??(4) 24-hour proteinuria >1g or UACR >=800 mg/g;?? ??(5) 30 <= eGFR <= 90 mL/min/1.73m².?
Exclusion criteria
Exclusion criteria: ??(1) Kidney transplant recipients;?? ??(2) Patients with systemic diseases that may cause mesangial IgA deposition, including but not limited to Henoch-Schönlein purpura, systemic lupus erythematosus, dermatitis herpetiformis, and ankylosing spondylitis;?? ??(3) Patients with other glomerular diseases or concurrent nephrotic syndrome;?? ??(4) Patients with acute, chronic, or latent infectious diseases;?? ??(5) Patients with severe comorbid cardiac, hepatic, or pulmonary diseases;?? ??(6) Patients with hypersensitivity to study medications;?? ??(7) Patients with malignancies;?? ??(8) Patients with a history of significant upper gastrointestinal (GI) disorders, such as peptic ulcer disease, esophagitis, or severe dyspepsia;?? ??(9) Patients who are pregnant, lactating, or planning pregnancy;?? ??(10) Patients with psychiatric disorders or inability to adhere to follow-up;?? ??(11) Other conditions deemed unsuitable for study participation by investigators.??
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Urine Albumin-to-Creatinine Ratio (UACR);24-hour urinary protein quantity;Serum Albumin;urine volume; | — |
Secondary
| Measure | Time frame |
|---|---|
| creatinine;estimated glomerular filtration rate;Cystatin C; | — |
Countries
China
Contacts
Public ContactLijie He
The First Affiliated Hospital of Air Force Medical University
Outcome results
None listed